Plasma cfDNA in Glioblastoma—Letter [PDF]
Clinical Cancer Research, 2020 We read enthusiastically the recent article by Bagley and colleagues ([1][1]). The authors prospectively investigated plasma cell-free DNA (cfDNA) concentration and mutations in patients with glioblastoma. This is an interesting topic and we commend the authors for their efforts.
Takeshi, Takayasu +2 more
openaire +2 more sources
cfDNA Sequencing: Technological Approaches and Bioinformatic Issues [PDF]
Pharmaceuticals, 2021 In the era of precision medicine, it is crucial to identify molecular alterations that will guide the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) released by the tumor in body fluids, like blood, and carrying its molecular characteristics is becoming a powerful biomarker for non-invasive detection and monitoring
Elodie Bohers +2 more
openaire +5 more sources
Genome‐wide cfDNA testing of maternal blood [PDF]
Ultrasound in Obstetrics & Gynecology, 2020 post-print 0,99 ...
Jani J. C. +8 more
openaire +4 more sources
Plasma cfDNA in Glioblastoma—Response
Clinical Cancer Research, 2020 We appreciate the interest in our study from Takayasu and colleagues. They raise important issues which were largely addressed in our article but deserve further discussion. Takayasu and colleagues question whether variants detected in plasma in our study reflect tumor somatic mutations.
Stephen J, Bagley, Erica L, Carpenter
openaire +3 more sources
Кардиоваскулярная терапия и профилактика, 2022 The search for early disease markers and the development of diagnostic systems has recently been expanding within genomics. Genomic deoxyribonucleic acid (DNA), cell-free DNA (cfDNA) and microbiome DNA obtained from different types of samples (tissues ...
V. A. Kondratskaya +6 more
doaj +1 more source
Requiring Caution in the Interpretation of Donor-Derived Cell-Free DNA Levels During Cancer Treatment in a Kidney Transplant Recipient.: A Case Report. [PDF]
IJU Case RepABSTRACT Introduction Donor‐derived cfDNA (dd‐cfDNA) indicates allograft rejection when > 1% of total cfDNA, but tumor‐derived cfDNA can interfere in cancer patients. Case Presentation A 61‐year‐old male kidney transplant recipient with metastatic renal cell carcinoma (RCC) initiated avelumab and axitinib.
Katsurayama N +9 more
europepmc +2 more sources
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. [PDF]
, 2017 Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications.
Alva, Ajjai S +31 more
core +1 more source
Liquid biopsy in CNS tumors: Current status & future perspectives
Indian Journal of Pathology and Microbiology, 2022 Precise classification of central nervous system (CNS) malignancies is vital for the treatment and prognostication. Identification of noninvasive markers can be of importance to guide treatment decisions and in monitoring treatment response.
Nuzhat Husain +3 more
doaj +1 more source
Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies [PDF]
, 2015 Objectives To report clinical implementation of cell‐free DNA (cfDNA) analysis of maternal blood in screening for trisomies 21, 18 and 13 in twin pregnancies and examine variables that could influence the failure rate of the test.
BEVILACQUA, ELISA +7 more
core +1 more source
Urine-Based Cell-Free DNA Tests in Urothelial Cancer: Additional Value for Clinical Decision-Making?
Société Internationale d’Urologie Journal, 2023 None.
Lars Dyrskjøt
doaj +1 more source